Cyclooxygenase-1 variant (COX-1v) (COX-1v)

Cyclooxygenase-1 variant (COX-1v), also known as COX-3, is a splice variant of the PTGS1 gene that retains intron 1 in its mature mRNA. It was first identified in the canine brain and proposed as the primary central target for acetaminophen (paracetamol) and other antipyretic analgesics, explaining their ability to reduce pain and fever without significant peripheral anti-inflammatory effects or gastrointestinal toxicity (Simmons et al., 2002; Warner & Mitchell, 2002). In humans, the COX-1v mRNA contains a frameshift mutation that has led to significant debate regarding the existence of a functional protein; however, it remains a key subject of pharmacological research into central pain processing and thermoregulation (Dinchuk et al., 2003). The enzyme is primarily localized in the central nervous system, including the cerebral cortex and hypothalamus, where it facilitates the biosynthesis of prostaglandins like PGE2 (Chandrasekharan et al., 2002). Drugs that interact with COX-1v, such as dipyrone and phenacetin, are thought to inhibit its catalytic activity to exert their therapeutic effects. Despite the controversy surrounding its human functionality, COX-1v represents a distinct pathway for understanding the mechanism of non-NSAID analgesics and potentially developing new treatments for pain and fever with fewer side effects. Research also suggests that COX-1v may be overexpressed in certain cancers, such as ovarian cancer, indicating a potential role beyond central nervous system signaling (Daikoku et al., 2005). Overall, COX-1v serves as a critical, albeit controversial, molecular target for understanding the central actions of common over-the-counter analgesics.

Other names

COX-3Cyclooxygenase-3COX-1bCOX-1 splice variant 1PCOX-1aProstaglandin-endoperoxide synthase 1 variant

Inhibition of prostaglandin synthesis in the central nervous system, specifically targeting the COX-1 variant enzyme to reduce pain and fever.